Atrizin60 ml

Cetirizine Hydrochloride [Oral] is a second-generation, selective H1-receptor antagonist indicated for the relief of allergic symptoms in adults and children. It is used in the following conditions:

• Seasonal Allergic Rhinitis (SAR): Relieves sneezing, runny nose, nasal congestion, and itchy or watery eyes triggered by seasonal allergens such as pollen, grass, and mold.
• Perennial Allergic Rhinitis (PAR): Controls persistent year-round allergic nasal symptoms caused by allergens such as house dust mites, pet dander, and cockroach particles.
• Chronic Idiopathic Urticaria (CIU): Treats uncomplicated skin manifestations of chronic idiopathic urticaria (hives), including itching, wheals, and skin redness without an identifiable underlying cause.
• Allergen-Induced Asthma: Used as adjunctive therapy to help reduce airway hypersensitivity triggered by allergic exposures in susceptible individuals.

Note: Always take Cetirizine Hydrochloride as directed by a registered physician. Self-medication without professional advice is not recommended.

Sedating Anti-histamine

Atrizin 60 ml is a potent, selective H1-receptor antagonist belonging to the second generation of antihistamines. It works by competitively blocking histamine at the H1 receptor site, preventing the allergic response triggered by histamine release from mast cells and basophils.

Cetirizine inhibits the histamine-mediated early phase of the allergic reaction, which causes immediate symptoms such as itching, sneezing, and watery eyes. It also reduces the migration of inflammatory cells (eosinophils, neutrophils, basophils) and suppresses the release of mediators associated with the late phase of the allergic response. This dual-phase inhibition makes Cetirizine particularly effective for sustained allergy control.

Unlike first-generation antihistamines, Cetirizine has no significant anticholinergic or antiserotonic effects. At pharmacologically active doses, it produces minimal sedation and does not cause clinically significant behavioral or cognitive changes, making it well suited for daytime use.

Pharmacokinetics

Atrizin 60 ml has a favorable drug interaction profile. No clinically significant drug interactions have been identified in formal pharmacokinetic studies with commonly co-administered drugs including Theophylline, Azithromycin, Pseudoephedrine, Ketoconazole, and Erythromycin.

However, caution is advised when Cetirizine is used alongside alcohol or other CNS depressants (such as sedatives or anxiolytics), as they may potentiate drowsiness in susceptible individuals even at therapeutic doses.

Always inform your physician and pharmacist of all medications, supplements, and herbal products you are currently taking before starting Cetirizine Hydrochloride.

Atrizin 60 ml is generally well tolerated. As a second-generation antihistamine, it has a significantly lower incidence of sedation compared to first-generation agents. However, some adverse effects may still occur, particularly at higher doses or in sensitive individuals.

Common side effects include:

• Somnolence (Drowsiness): The most frequently reported side effect. Occurs more often at higher doses; patients should exercise caution when driving or operating machinery.
• Dry Mouth (Xerostomia): Mild anticholinergic effect, less prominent than with first-generation antihistamines.
• Fatigue / Asthenia: General tiredness may occur, particularly when initiating therapy.
• Headache: Usually mild and transient.

Less common side effects include:

• Gastrointestinal Discomfort: Nausea, abdominal pain, or diarrhea in some patients.
• Pharyngitis / Cough: Mild throat irritation or cough.

Rare but serious: Hypersensitivity reactions including rash, angioedema, or anaphylaxis. Discontinue immediately and seek medical attention if these occur.

If you experience any serious or persistent side effects, stop use and consult your physician promptly.

Atrizin 60 ml is classified as US FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk; however, no adequate and well-controlled studies in pregnant women are available. Because animal studies are not always predictive of human response, Cetirizine should be used during pregnancy only if clearly needed and under the direct supervision of a physician.

The risk during the first trimester is not fully established. Use should be avoided unless the potential benefit to the mother clearly outweighs the potential risk to the fetus.

Atrizin 60 ml has been shown to be excreted in human breast milk. Because of the potential for adverse reactions in nursing infants, caution is strongly advised. A physician should be consulted to weigh the benefits of breastfeeding against the potential risks to the infant before initiating therapy in a nursing woman.

Always consult your obstetrician or healthcare provider before using any medication during pregnancy or breastfeeding.

Although Atrizin 60 ml is a low-sedating antihistamine, the following precautions must be observed during treatment:

• Driving & Operating Machinery: Caution is advised when driving or operating heavy machinery, as drowsiness may occur in some patients — particularly at higher doses or when combined with alcohol.
• Alcohol: Avoid alcohol during therapy, as it may enhance CNS depressant effects and increase sedation.
• Renal Impairment: Clearance is reduced and half-life prolonged in patients with renal impairment. Dose adjustment based on creatinine clearance is recommended.
• Hepatic Impairment: Hepatic dysfunction reduces Cetirizine clearance, increasing AUC and half-life by 2–3 fold. Careful monitoring and dose adjustment are recommended.
• Pediatric Patients with Renal/Hepatic Impairment: The injectable form is not recommended in children under 6 years of age with impaired renal or hepatic function.
• CNS Depressants: Co-administration with sedatives, anxiolytics, or other CNS depressants should be approached with caution due to a risk of additive somnolence.

Inform your doctor about all existing medical conditions and current medications before starting Cetirizine Hydrochloride therapy.

Atrizin 60 ml has a wide therapeutic margin; however, overdose — particularly in children — requires immediate medical attention. Symptoms are generally extensions of the drug's known pharmacological effects.

Signs and Symptoms: Excessive sedation, drowsiness, restlessness or agitation (especially in children), urinary retention, dry mouth, tachycardia, and in severe cases, seizures or altered consciousness.

Reported Overdose: Overdose with 150 mg (15 times the standard dose) has been reported in adults, with somnolence as the primary symptom. No life-threatening outcome was recorded in this case.

Management: There is no specific antidote for Cetirizine overdose. Treatment is symptomatic and supportive. Gastric lavage may be considered if ingestion is recent. Activated charcoal may be administered under medical supervision. Hemodialysis is not effective in removing Cetirizine due to its high protein binding.

In case of suspected overdose, seek emergency medical assistance immediately or contact a poison control center. Do not attempt to self-treat.

Keep all medications, including Cetirizine Hydrochloride, out of the reach of children to prevent accidental ingestion.

Store Atrizin 60 ml under the following conditions to maintain its potency and safety:

• Store at room temperature, below 30°C.
• Keep in a dry place, away from humid environments such as bathrooms or kitchens.
• Protect from direct light and sunlight; keep in the original packaging until use.
• Keep out of the reach and sight of children at all times.
• Do not use after the expiry date printed on the packaging.
• Dispose of unused or expired medication safely according to local regulations — do not flush down the drain or discard in household waste.

Improper storage may affect the potency and safety of the medication. Always check the expiry date before use.

Certain patient populations require special consideration when using Atrizin 60 ml due to altered pharmacokinetics or increased sensitivity.

Hepatic Impairment: In patients with mild to moderate hepatic impairment, total body clearance of Cetirizine is reduced, and both the AUC and elimination half-life are increased approximately 2–3 fold compared to healthy subjects. Dose reduction should be considered.

Renal Impairment: Renal clearance of Cetirizine decreases in proportion to the decline in creatinine clearance. Plasma levels are unaffected by hemodialysis. In patients on dialysis, the elimination half-life is extended to approximately 20 hours and AUC increases by about threefold. Dosage adjustment is necessary in these patients.

Pediatric Use: The safety and efficacy of Cetirizine have been demonstrated in pediatric patients from 6 months to 5 years of age for the treatment of allergic rhinitis and chronic urticaria. Age-appropriate formulations (syrup and pediatric drops) are available. The injectable form is not recommended in children under 6 years with impaired renal or hepatic function.

Elderly Patients (≥ 65 years): Cetirizine clearance is reduced in elderly patients proportionally to the age-related decline in creatinine clearance. Reduced doses or extended dosing intervals may be appropriate, particularly in elderly patients with concurrent renal insufficiency.

Always individualize the dosage for special populations under the guidance of a qualified healthcare professional.